home / stock / tcrr / tcrr news

TCRR News and Press, TCR2 Therapeutics Inc. From 05/12/22

Stock Information
Company Name: TCR2 Therapeutics Inc.
Stock Symbol: TCRR
Market: NASDAQ
Website: tcr2.com
Menu
TCRR TCRR Quote TCRR Short TCRR News TCRR Articles TCRR Message Board
Get TCRR Alerts

News, Short Squeeze, Breakout and More Instantly...
TCRR - TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial - IND Clearance for Phase 1/2 clinical trial of TC-510 - 30 patients treated with gavo-cel in the expanded Phase 1 trial; dataset review in July 2022 - Updates anticipated in the second half of 2022 CAMBR...
TCRR - TCR2 Therapeutics leads healthcare gainers; ORIC Pharmaceuticals, Graphite Bio among losers

Gainers: TCR2 Therapeutics (TCRR) +16%. Precision BioSciences (DTIL) +16%. Alzamend Neuro (ALZN) +15%. BioSig Technologies (BSGM) +13%. Applied Therapeutics (APLT) +13%. Losers: ORIC Pharmaceuticals (ORIC) -29%. Applied Genetic Technologies (AGTC) -28%. NeuroSense Therapeutics (NRSN...

TCRR - TCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04

TCR2 Therapeutics press release (NASDAQ:TCRR): Q4 GAAP EPS of -$0.72 beats by $0.04. Cash, cash equivalents, and investments of $265.6M as of December 31, 2021 compared to $228.0 million as of December 31, 2020 For further details see: TCR2 Therapeutics GAAP EPS of -$0.72 beat...

TCRR - TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the fourth quarter ended De...
TCRR - TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced it will present a poster at the American Association of ...

TCRR - TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that on February 28, 2022 (the “Grant Date”...

TCRR - TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside cha...
TCRR - TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Bus...

TCRR - TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x10 8 cells/m 2 - Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022 - Initial data from TC-510 Phase 1/2 trial anticipated in 2H 2022 - Selection of lead allo...

TCRR - TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/ TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Men...
Previous 10 Next 10